

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Problem Image Mailbox.**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	
Jing WU et al.	)	Group Art Unit: 1624
Application No.: 09/916,440	)	Examiner: B. Kifle
Filed: July 30, 2001	)	Confirmation No.: 2003
For: CYCLOALKYL, LACTAM, LACTONE	)	
AND RELATED COMPOUNDS,	)	
PHARMACEUTICAL COMPOSITIONS	)	
COMPRISING SAME, AND METHODS	)	
FOR INHIBITING $\beta$ -AMYLOID	)	
PEPTIDE RELEASE AND/OR ITS	)	
SYNTHESIS BY USE OF SUCH	)	
COMPOUNDS	)	

**INFORMATION DISCLOSURE STATEMENT**  
**TRANSMITTAL LETTER**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☐ No additional fee for submission of an IDS is required.
- ☒ The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \$\_\_\_\_\_ to Deposit Account No. 02-4800 for the fee due.
- ☒ A check in the amount of \$ 180.00 is enclosed for the fee due.


The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

By:

  
Erin M. Dunston  
Registration No. 51,147

Date: December 19, 2002

DOCKETED *gms*  
filed 12-19-02 (12/02)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	
Jing WU et al.	)	Group Art Unit: 1624
Application No.: 09/916,440	)	Examiner: B. Kifle
Filed: July 30, 2001	)	Confirmation No.: 2003
For: CYCLOALKYL, LACTAM, LACTONE	)	
AND RELATED COMPOUNDS,	)	
PHARMACEUTICAL COMPOSITIONS	)	
COMPRISING SAME, AND METHODS	)	
FOR INHIBITING $\beta$ -AMYLOID	)	
PEPTIDE RELEASE AND/OR ITS	)	
SYNTHESIS BY USE OF SUCH	)	
COMPOUNDS	)	

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited below is enclosed.

**Foreign Patents**

1.	EP 0 591 529	4/13/94	Europe
2.	EP 0 647 632	4/12/95	Europe
3.	EP 0 945 445	9/29/99	Europe
4.	WO 92/11246	07/09/92	PCT
5.	WO 94/00438	01/06/94	PCT
6.	WO 94/25445	11/10/94	PCT
7.	WO 95/03285	02/02/95	PCT

Supplemental Information Disclosure Statement

Application No. 09/916,440

Attorney's Docket No. 002010-586

Page 2

8.	WO 98/25911	06/18/98	PCT
9.	5247033	09/24/93	Japan
10.	6211812	08/02/94	Japan
11.	10101560	04/21/98	Japan

European Patent No. 0591529 is the English language equivalent of WO 92/11246;  
European Patent No. 0647632 is the English language equivalent of WO 94/00438 and  
European Patent No. 0945445 is the English language equivalent of WO 98/25911.

A fee in the amount of \$180.00 (126) is enclosed in conformance with 37 C.F.R.  
§ 1.97(c).


To assist the Examiner, the documents are listed on the attached form PTO-1449. It  
is respectfully requested that an Examiner initialed copy of this form be returned to the  
undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: December 19, 2002

By:

  
Erin M. Dunston  
Registration No. 51,147

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(650) 622-2300

Substitute for form 1449A/PTO  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	ATTORNEY'S DKT NO. 002010-586	APPLICATION NO. 09/916,440
	APPLICANT Jing WU et al.	
	FILING DATE July 30, 2001	GROUP 1624

U.S. PATENT DOCUMENTS				
Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	no
	0591529		Europe	4/13/94		
	0647632		Europe	4/12/95		
	0945445		Europe	9/29/99		
	WO 92/11246		PCT	7/9/92		
	WO 94/00438		PCT	1/6/94		
	WO 94/25445		PCT	11/10/94		
	WO 95/03285		PCT	2/2/95		
	WO 98/25911		PCT	6/18/98		
	5247033		Japan	9/24/93		
	6211812		Japan	8/2/94		
	10101560		Japan	4/21/98		

NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
Examiner Signature	Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of	)	
Jing Wu, et al.	)	Group Art Unit: 1624
Application No.: 09/916,440	)	Examiner: B. Kifle
Filed: July 30, 2001	)	
For: CYCLOALKYL, LACTAM, LACTONE	)	
AND RELATED COMPOUNDS,	)	
PHARMACEUTICAL COMPOSITIONS	)	
COMPRISING SAME, AND METHODS	)	
FOR INHIBITING $\beta$ -AMYLOID	)	
PEPTIDE RELEASE AND/OR ITS	)	
SYNTHESIS BY USE OF SUCH	)	
COMPOUNDS	)	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
TRANSMITTAL LETTER

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Enclosed is a Supplemental Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☐ No additional fee for submission of an IDS is required.
- ☒ The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.97(p) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \$\_\_\_\_\_ to Deposit Account No. 02-4800 for the fee due.
- ☒ A check in the amount of \$ 180.00 is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: 9-4-02  
P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(650)622-2300

By: Gerald F. Swiss  
Gerald F. Swiss  
Registration No. 30,113

DOCKETED  
filed 9-5-02  
Hana  
Mig

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of )  
Jing Wu, et al. ) Group Art Unit: 1624  
Application No.: 09/916,440 ) Examiner: B. Kifle  
Filed: July 30, 2001 )  
For: CYCLOALKYL, LACTAM, LACTONE )  
AND RELATED COMPOUNDS, )  
PHARMACEUTICAL COMPOSITIONS )  
COMPRISING SAME, AND METHODS )  
FOR INHIBITING  $\beta$ -AMYLOID )  
PEPTIDE RELEASE AND/OR ITS )  
SYNTHESIS BY USE OF SUCH )  
COMPOUNDS )

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited below is enclosed.

**U.S. Patents**

2,938,029	Brenner et al.	5/24/60
3,598,859	Yates et al.	8/10/71
4,080,449	Croisier et al.	3/21/78
4,460,579	Karenwesky	7/17/84
5,478,857	Clemens et al.	12/26/95
5,658,901	Claremon et al.	8/19/97

**DOCKETED**  
filed 9.5.02 (59/5100)  
Hana  
Carly

Foreign Patents

0 061 187	9/29/82	Europe
810221A		Europe
WO 92/16524	10/1/92	PCT
WO 95/25117	9/21/95	PCT
WO 96/25408	8/22/96	PCT
WO 96/29313	9/26/96	PCT
WO 97/38705	10/23/97	PCT
WO 98/04539		PCT
WO 97/16410	5/9/97	PCT
WO 98/22494	5/28/98	PCT
WO 98/22430	5/28/98	PCT
WO 98/22433	5/28/98	PCT
WO 98/22494	5/28/98	PCT
WO 98/38177	9/3/98	PCT
GB 1,519,495	7/26/78	UK
HU 71515B	12/28/95	Hungary (abstract only)
179757		Japan

Non-Patent References

Akhatar, et al., "Bicyclic Imides with Bridgehead Nitrogen..", *J. Org. Chem.*, 55: pp. 5222-5225 (1990).

Armstrong, et al., "An Efficient Asymmetric Synthesis of (R)-3-Amino-2,3,4,5-tetrahydro-1H-[1]benzazepin-2-one", *Tetrahedron Letters*, 35: pp. 3239-3242 (1994).

Barton, et al., "A New Rearrangement of Ketonic Nitrones...", *J. Chem. Soc.*, pp. 1764-1767 (1975).

Ben-Ishai, et al., "Intra vs Intermolecular Amidoalkylation of Aromatics", *Tetrahedron*, 43:2, pp. 439-450 (1987).



Blade-Font, "Facile Synthesis of  $\gamma$ -,  $\delta$ -, and  $\epsilon$ -lactams by Cyclodehydration of  $\omega$ -amino Acids on Alumina or Silica Gel", *Tetrahedron Letters*, 21: 2443-2446 (1980).

Brown, et al., "A Revision of the Structure of "7-Phenyloxindole", *Tetrahedron Letters*, 8: pp. 667-670 (1971).

Burkholder, et al., "The Synthesis of 6-Amino-5-Oxo-7-Phenyl-1,4-Oxazepines As Conformationally Constrained *Cauche* (-) Dipeptide Mimetics", *Biog. Med. Chem. Letter*, 2: p. 231 (1993).

Busacca, et al., "Synthesis of Novel Tetrahydrobenzazepinones", *Tetrahedron Letters*, 33:2, pp. 165-168 (1992).

Butcher, et al., "Preparation of 3-Amino-1,4-Benzodiazepin-2-Ones Via Direct Azidation with Trisyl Azide", *Tetrahedron Letters*, 37:37, pp. 6685-6688 (1996).

Chartier-Harlin, et al., "Early-onset Alzheimer's disease caused by mutations at codon 717 of the  $\beta$ -Amyloid precursor protein gene.", *Nature*. 353:31, pp. 844-846 (1991).

Citron, et al., "Mutation of the  $\beta$ -amyloid precursor protein in familial Alzheimer's disease increases  $\beta$ -amyloid protein production.", *Nature* 360:672-674 (1992).

Clark, et al., "Effects of Remote *N*-(*tert*-Butoxycarbonyl) Groups on Heteroatom Directed Lithiation at Benzylic Positions", *Tetrahedron*, 49:7, pp. 1351-1356 (1993).

Colombo, et al., "Synthesis of 7,5-Fused Bicyclic Lactams by Stereoselective Radical Cyclization", *Tetrahedron Letters*, 35:23, pp. 4031-4034 (1994).

Cornille, et al., "Electrochemical Cyclization of Dipeptides Toward Novel Cicyclic, Reverse-Turn Pepidomimetics", *J. Am. Chem. Soc.*, 117: pp. 909-917 (1995).

Crombie, et al., "Transamidation Reactions of  $\beta$ -Lactams", *Tetrahedron Letters*, 27:42, pp. 5151-5154 (1986).

Curran, et al., "A Short synthesis of Bicyclic Dipeptides Corresponding to Xxx-L-Pro and Xxx-D-Pro Having Constrained *Cis*-Proline Amides", *Tetrahedron Letters*, 36, pp. 191-194 (1995).

Das, et al, "Dual Metalloprotease Inhibitors IV", *Biorg. Med. Chem. Lett.*, 4:18, pp. 2193-2198 (1994).

Desai, et al., "Polymer Bound EDC (P-EDC): A convenient Reagent for Formation of An Amide", *Tetrahedron Letters*, 34:48, pp. 7685-7688 (1993).

Dickerman, et al., "Studies in Piperidone Chemistry", *J. Org. Chem.*, 14, p. 530-536 (1949).

Dickerman, et al., "The Schmidt Reaction with 2,2,6-Trimethyl-And 1,3-Dimethyl-4-Piperidones", *J. Org. Chem.*, 20: p. 206-209 (1955).

Dickerman, et al., "The Schmidt Reaction with 3-Ethoxycarbonyl-4-Piperidones and the synthesis of six 5-homo-piperazinones", *J. Org. Chem.*, 19, p. 1855-1861 (1954).

Donaruma, et al., Organic Reactions, Ch. 1, "The Beckmann Rearrangement", pp. 1-156 (1960).

Edwards, et al., "Cyclization and Fragmentation of N-Chloro Lactams", *Can. J. Chem.*, 49: pp. 1648-1658 (1971).

Flynn et al., "Applications of a Conformationally Restricted Phe-Leu Dipeptide Mimetic to the Design of a Combined Inhibitor of Angiotensin I-Converting Enzyme and Neutral Endopeptidase 24.11", *J. Med. Chem.*, 36: pp. 2420-2423 (1993).

Freidinger et al, "Protected Lactam-Bridged Dipeptides for Use as Conformational Constraints in Peptides", *J. Org. Chem.*, 47: pp. 104-109 (1982).

Gaetzi, "Fungicidal Amino azacycloheptanones", *Chem. Abs.*, 66: 28690m.

Games, et al., "Alzheimer-type Neuropathology In Transgenic Mice Overexpressing V717F  $\beta$ -amyloid Precursor Protein", *Letters to Nature*, 373: pp. 523-527 (1995).

Glenner, et al. "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein." *Biochem. Biophys. Res. Commun.* 120(3): 885-890 (1984).

Goate, et al. "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease." *Letters to Nature*. 349: 704-706 (1991)

- Gracias, et al., "Efficient Nitrogen Ring-Expansion Process Facilitated by in Situ Hemiketal Formation", *J. Am. Chem. Soc.*, 117: pp. 8047-8048 (1995).
- Grunewald, et al., "Effect of Ring Size or an Additional Heteroatom on the Optency and Selectivity of Bicyclic Benzylamine-Type Inhibitors of Phenylethanolamine *N*-Methyltransferase", *J. Med. Chem.*, 39, pp. 3539 (1996).
- Hansen, et al., "Re-examination and further Development of a Precise and Rapid Dye Method for Measuring Cell Growth", *J. Immun. Meth.*, 119: pp. 203-210 (1989).
- Hart, et al., "The Ester Enolate-Imine Condensation Route to  $\beta$ -Lactams", *Chem. Rev.*, 89: pp. 1447-1465 (1989).
- Herschmann, "Recherches sur la nature du Methonitrile de Wallach", *Helv. Chim. Acta*, 7:329, p. 2537-2547 (1949).
- Hoffman, et al., "Efficient Synthesis of *N*-Substituted Lactams from (*N*-Arylsulfonyloxy) Amines and Cyclic Ketones", *Tetrahedron Letters*, 30: pp. 4207-4210 (1989).
- Hoffman, et al., "Synthesis and Structure of 7-Methyl-and 7-Pheynl-1,2,3,4-Tetrahydro-1,4-Diazepin-5-ones", *Tetrahydrodiazepinones*, 27: p. 3565 (1962).
- Holladay, et al., "Synthesis of  $\alpha$ -Benzyl  $\gamma$ -Lactam,  $\alpha$ -Benzyl  $\delta$ -Lactam and  $\alpha$ -Benzylproline Derivatives as Conformationally Restricted Analogues of Phenylalaninamide", *J. Org. Chem.*, 56: 3900-3905 (1991).
- Hu, et al., "Two Efficient Syntheses of (+)-*anti*-*N*-Benzyl-3-Amino-4-Hydroxyhexahydroazepine", *Tetrahedron Letters*, 36:21, pp. 3659-3662 (1995).
- Itoh, K., "Synthesis and Antiotensin Converting Enzyme-Inhibitory Activity of 1,5-benzothiazine...", *Chemical Abstracts*, Vol. 111, No. 15, 10/9/89, Columbus, OH, Astract No. 126464h.
- Johnson-Wood, et al. "Amyloid precursor protein processing and  $A\beta_{42}$  deposition in a transgenic mouse model of Alzheimer's disease." *PNAS USA*. 94: 1550-1555 (1997).
- Kawase, et al., "Electrophilic Aromatic Substituion with *N*-Methoxy-*N*-Acylnitrenium Ions Generated from *N*-Chloro-*N*-Methoxyamies", *J. Org. Chem.*, 54: pp. 3394-3403 (1989).
- King, et al., "Iodotrimthylsilane-Mediated 2-Mononhalogenation of 4-aza-5 $\alpha$ -androstan-3-one Steriods", *J. Org. Chem.* 58: pp. 3384 (1993).

Kitagawa, et al., "Structural Analysis of  $\beta$ -Turn Mimics Containing a Substituted 6-Aminocaproic Acid Linker", *J. Am. Chem. Soc.*, 117: pp. 5169-5178.

Klölč, "Amino Acids and Peptides LXXXIX Synthesis of L-4-Azalsine, D-4-Azalsine, and L-4-Azalsine- $[6-^{14}\text{C}]$ " *Coll. Czech. Chem. Comm.*, 34, pp. 630 (1969).

Kametani, et al., "A Simple Synthesis of 4-Thiazolidones, Tetrahydro-1,3-Thiazin-4-One and Hexahydro-1,3-Thiazepin-4-Ones from Amide-Thiols", *Heterocycles*, 9: pp. 831-840 (1978).

Krimm, "Über Isonitron", *Chem. Ber.*, 91: p. 1057 (1958).

Krow, et al., "Regioselective Functionalization", *J. Org. Chem.*, 61: pp. 5574-5580 (1996).

Ksander, G.M., et al. "Dual Angiotensin Converting Enzyme/Thromboxane Synthase Inhibitors.", *J. Med. Chem.* 37: 1823-1832 (1994).

Kukulja, et al., "Orally Absorbable Cephalosporin Antibiotics", *J. Med. Chem.*, 28:12, pp. 1886 (1985).

Losse, G., et al., "Synthese Des Depsipeptides Valinomycin", *Tetrahedron*, 27, pp. 1423-1434 (1971).

Lowe, et al., "5,7-Diphenyl-3-Ureido-hexahydroazepin-2-Ones as Cholecystokinin-B Receptor Ligands", *Bioorg & Med Chem Letters*, 4:24, pp. 2877-2882 (1994).

McKennis, et al., "The Synthesis of Hydroxycotinine and Studies on Its Structure", *Synthesis and Hydroxycotinine*, pp. 383-387 (1963).

Micouin, et al., "Asymmetric Synthesis", *Tetrahedron*, 52:22, pp. 7719-7726 (1996).

Miller, et al., "Application of Ring-Closing Metathesis to the Synthesis of Rigidified Amino Acids and Peptides", *J. Am. Chem. Soc.*, 118, pp. 9606-9614 (1996).

Mullan, et al., "A Pathogenic Mutation for Probable Alzheimer's Disease in the APP Gene at the N-Terminus of  $\beta$ -Amyloid", *Nature Genetics* 1, pp. 345-347 (1992).

Murrell, et al., "A Mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease", *Reports*, pp. 97-99 (1991).

Nedenskov, et al., "Synthesis of Potential Hypnotics", *Acta. Chem. Scand.*, 12:7, pp. 1404-1410 (1958).

Ogliaruso and wolfe, *Synthesis of Lactones and Lactams*, Patai, et al., Ed., J. Wiley & Sons, NY:NY, (1993).

Orito, et al., "Benzolactams-1", *Tetrahedron*, 36:8, pp. 1017-1021 (1980).

Overberger, et al., "Optically Active Polyamides", *Brooklyn Polytechnic*, pp. 3431-3435 (1963).

Overberger et al., "The Synthesis of Optically Active C-Methyl-2-oxoheptamethyleminines and C-Methyl-7-aminoheptanoic Acids", *Macromolecules*, 1:1, pp. 1-6 (1968).

Parsons, et al., "Benzolactams. A New Class of Converting Enzyme Inhibitors", *Biochem. Biophys. Res. Comm.*, 117: pp. 108-113 (1983).

Pedersen, et al., "Studies on Organophosphorus Compounds", *Tetrahedron*, 35: p. 2433 (1979).

Reupple, et al., "Abberant Alkaloid Biosynthesis", *J. Am. Chem. Soc.*, 93: 7021 et seq. (1971).

Robl, et al., "Synthesis of Benzo-Fused, 7,5-and 7,6-Fused Azepinones and Conformationally Restricted Dipeptide Mimetics", *Tetrahedron Lett.*, 36:10, pp. 1593-1596 (1995).

Robl, et al., "Dual Metalloprotease Ihibitors", *Bioorg. Med. Che. Letter*, 4: pp. 1789-1794 (1994).

Rodriguez, et al., "Conformationally Restricted Analogues of Methionine", *Tetrahedron*, 52: pp. 7727-7736 (1996).

Sekakida, et al., "Studies on Seven-membered Heterocyclic Compounds Containing Nitrogen", *Bull. Chem. Soc. Japan*, 44: pp. 478-480 (1971).

Selkoe, et al. "Amyloid Protein and Alzheimer's Disease." *Scientific American*. 68-78 (1991).

Selkoe, et al. "The Molecular Pathology of Alzheimer's Disease." *Neuron*. 6:487-498 (1991).

Shirota, et al., "Potential Inhibitors of Collagen Biosynthesis", *J. Med. Chem.*, 20: pp. 1623-1627 (1977).

Skiles, et al., "Eleastase Inhibitors Containing Conformationally Restricted Lactams", *Bioorg. Med. Chem. Letter*, 3: pp. 773-778 (1993).

Slusarchyk, et al., "Dual Metalloprotease Inhibitors.V.", *Bioorg. med. Chem. Lett.*, 5: pp. 753-758 (1995).

Smith, et al., "The Curtius Reaction", *Organic Reactions*, Ch. 9, pp. 337-449 (1946).

Suda, et al., "Metalloporphyrin-catalysed Rearrangement of Oxaziridines", *J. Chem. Soc. Chem. Comm.*, pp. 949-950 (1994).

Thomas, et al, "Nuclear Magnetic Resonance Studies and Conformational Analysis of Bicyclic Inhibitors of Angiotensin-converting Enzyme", *J. Chem. Soc. Perkin II*, 747 (1986).

Ugi, et al., "Ugi Reactions with Trifunctional  $\alpha$ -Amino Acids, Aldehydes, Isocyanides and Alcohols", *Tetrahedron*, 52:35, pp. 11657-11664 (1996).

Van der Steen, et al., "Synthesis of 3-Amino-2-Azetidinones: A Literature Survey", *Tetrahedron Letters*, 47: pp. 7503-7524 (1991).

Vedejs, et al., "Synthesis of N-Methoxy and N-H Aziridines from Alenes", *Tetrahedron Letters*, 33: pp. 3261-3264 (1992).

Wada, et al., "Stereospecific and Stereoselective Reactions", *Bull. Chem. Soc. Japan*, 46: pp. 2833-2835 (1973).

Wasserman, et al., "Total Synthesis of ( $\pm$ )-Dihydroperiphylline", *J. Am. Chem. Soc.*, 103, p. 461-462 (1981).

Wathey, et al., "Synthesis and Biological Properties of (Carboxyalkyl)amino-Substituted Bicyclic Lactam Inhibitors of Angiotensin converting Enzyme", *J. Med. Chem.*, 28: pp. 1511-1516 (1985).

Wheeler, et al., "Formation and Photochemical Wolff Rearrangement of Cyclic  $\alpha$ -Diazo Ketones", *Organic Syntheses*, Coll. Vol. VI, p. 840.

Wolff, "The Schmidt Reaction", Organic Reactions, ch. 8, pp. 307-336 (1946).

Yakoo, et al., "Studies on Seven-Membered Heterocyclic Compounds Containing Nitrogen", *Bull. Chem. Soc. Japan*, 29: p. 631 (1956).

Yanganasawa, et al., "Angiotensin-converting Enzyme Inhibitors", *J. Med. Chem.*, 30: p. 1984-1991 (1987).

Japanese patent application 179757 and published International Application No. WO 98/04539 have been cited merely for completeness of the record because both were cited by the Japanese examiner in the examination of the Japanese counterpart of the present application. Neither reference has an early enough effective reference date to be available as a reference against the present application. European patent application No. 810221A is the English language counter part of International Application No. WO 96/25408, already of record herein. Due to problems encountered in downloading EP 810221A, the copy provided herein is missing pages 327-336.

The chemistry text, "The Synthesis of Lactose and Lactams" has been cited in an exercise of caution because it is referenced in the application as a synthesis resource. Because the text is over 1,000 pages, Applicants have merely enclosed the table of contents for the book.

A fee in the amount of \$180.00 (126) is enclosed in conformance with 37 C.F.R. § 1.97(c).

To assist the Examiner, the documents are listed on the attached form PTO-1449.  
It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: <sup>1515</sup> 9-4-02

By: Gerald F. Swiss  
Gerald F. Swiss  
Registration No. 30,113

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(650) 622-2300



Substitute for form 1449A/PTO	ATTORNEY'S DKT NO. 002010-586	APPLICATION NO. 09/916,440
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	
	APPLICANT Jing Wu, et al.	
	FILING DATE July 30, 2001	GROUP 1624

U.S. PATENT DOCUMENTS						
Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)		
	Number	Kind Code (if known)				
	2,938,029		Brenner et al.	5/24/60		
	3,598,859		Yates et al.	8/10/71		
	4,080,449		Croisier et al.	3/21/78		
	4,460,579		Karenewsky	7/17/84		
	5,478,857		Clemens et al.	12/26/95		
	5,658,901		Claremon et al.	8/19/97		
FOREIGN PATENT DOCUMENTS						
Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	no
	0 061 187		Europe	9/29/82		
	810221A		Europe			
	WO 92/16524		PCT	10/1/92		
	WO 95/25117		PCT	9/21/95		
	WO 96/25408		PCT	8/22/96		
	WO 96/29313		PCT	9/26/96		
	WO 97/38705		PCT	10/23/97		
	WO 97/16410		PCT	5/9/97		
	WO 98/04539		PCT			
	WO 98/22494		PCT	5/28/98		
	WO 98/22430		PCT	5/28/98		
	WO 98/22433		PCT	5/28/98		
	WO 98/22494		PCT	5/28/98		
	WO 98/38177		PCT	9/3/98		
	GB 1,519,495		UK	7/26/78		
	HU 71515		Hungary	12/28/95		
	JP 179757		Japan	4/21/98		
NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	Akhtatar, et al., "Bicyclic Imides with Bridgehead Nitrogen..", <i>J. Org. Chem.</i> , 55: pp. 5222-5225 (1990).					
	Armstrong, et al., "An Efficient Asymmetric Synthesis of (R)-3-Amino-2,3,4,5-tetrahydro-1H-[1]benzazepin-2-one". <i>Tetrahedron Letters</i> , 35: pp. 3239-3242 (1994).					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO	ATTORNEY'S DKT NO.	APPLICATION NO.
	002010-586	09/916,440
	APPLICANT	
	Jing Wu, et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE	GROUP
	July 30, 2001	1624

	Barton, et al., "A New Rearrangement of Ketonic Nitrones...", <i>J. Chem. Soc.</i> , pp. 1764-1767 (1975).
	Ben-Ishai, et al., "Intra vs Intermolecular Amidoalkylation of Aromatics", <i>Tetrahedron</i> , 43:2, pp. 439-450 (1987).
	Blade-Font, "Facile Synthesis of $\gamma$ -, $\delta$ -, and $\epsilon$ -lactams by Cyclodehydration of $\omega$ -amino Acids on Alumina or Silica Gel", <i>Tetrahedron Letters</i> , 21: 2443-2446 (1980).
	Brown, et al., "A Revision of the Structure of "7-Phenyloxindole", <i>Tetrahedron Letters</i> , 8: pp. 667-670 (1971).
	Burkholder, et al., "The Synthesis of 6-Amino-5-Oxo-7-Phenyl-1,4-Oxazepines As Conformationally Constrained <i>Cauche</i> (-) Dipeptide Mimetics", <i>Biog. Med. Chem. Letter</i> , 2: p. 231 (1993)
	Busacca, et al., "Synthesis of Novel Tetrahydrobenzazepinones", <i>Tetrahedron Letters</i> , 33:2, pp. 165-168 (1992).
	Butcher, et al., "Preparation of 3-Amino-1,4-Benzodiazepin-2-Ones Via Direct Azidation with Trisyl Azide", <i>Tetrahedron Letters</i> , 37:37, pp. 6685-6688 (1996).
	Chartier-Harlin, et al., "Early-onset Alzheimer's disease caused by mutations at codon 717 of the $\beta$ -Amyloid precursor protein gene.", <i>Nature</i> . 353:31, pp. 844-846 (1991).
	Citron, et al., "Mutation of the $\beta$ -amyloid precursor protein in familial Alzheimer's disease increases $\beta$ -amyloid protein production.", <i>Nature</i> 360:672-674 (1992).
	Clark, et al., "Effects of Remote <i>N</i> -( <i>tert</i> -Butoxycarbonyl) Groups on Heteroatom Directed Lithiation at Benzylic Positions", <i>Tetrahedron</i> , 49:7, pp. 1351-1356 (1993).
	Colombo, et al., "Synthesis of 7,5-Fused Bicyclic Lactams by Stereoselective Radical Cyclization", <i>Tetrahedron Letters</i> , 35:23, pp. 4031-4034 (1994).
	Cornille, et al., "Electrochemical Cyclization of Dipeptides Toward Novel Cyclic, Reverse-Turn Peptidomimetics", <i>J. Am. Chem. Soc.</i> , 117: pp. 909-917 (1995).
	Crombie, et al., "Transamidation Reactions of $\beta$ -Lactams", <i>Tetrahedron Letters</i> , 27:42, pp. 5151-5154 (1986).
	Curran, et al., "A Short synthesis of Bicyclic Dipeptides Corresponding to Xxx-L-Pro and Xxx-D-Pro Having Constrained <i>Cis</i> -Proline Amides", <i>Tetrahedron Letters</i> , 36, pp. 191-194 (1995).
	Das, et al., "Dual Metalloprotease Inhibitors IV", <i>Biorg. Med. Chem. Lett.</i> , 4:18, pp. 2193-2198 (1994).
	Desai, et al., "Polymer Bound EDC (P-EDC): A convenient Reagent for Formation of An Amide", <i>Tetrahedron Letters</i> , 34:48, pp. 7685-7688 (1993).

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO	ATTORNEY'S DKT NO.	APPLICATION NO.
	002010-586	09/916,440
	APPLICANT	
	Jing Wu, et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE	GROUP
	July 30, 2001	1624

	Dickerman, et al., "Studies in Piperidone Chemistry", <i>J. Org. Chem.</i> , 14, p. 530-536 (1949).
	Dickerman, et al., "The Schmidt Reaction with 2,2,6-Trimethyl-And 1,3-Dimethyl-4-Piperidones", <i>J. Org. Chem.</i> , 20: p. 206-209 (1955).
	Dickerman, et al., "The Schmidt Reaction with 3-Ethoxycarbonyl-4-Piperidones and the synthesis of six 5-homo-piperazinones", <i>J. Org. Chem.</i> , 19, p. 1855-1861 (1954).
	Donaruma, et al., <i>Organic Reactions</i> , Ch. 1, "The Beckmann Rearrangement", pp. 1-156 (1960).
	Edwards, et al., "Cyclization and Fragmentation of N-Chloro Lactams", <i>Can. J. Chem.</i> , 49: pp. 1648-1658 (1971).
	Flynn et al., "Applications of a Conformationally Restricted Phe-Leu Dipeptide Mimetic to the Design of a Combined Inhibitor of Angiotensin I-Converting Enzyme and Neutral Endopeptidase 24.11", <i>J. Med. Chem.</i> , 36: pp. 2420-2423 (1993).
	Freidinger et al., "Protected Lactam-Bridged Dipeptides for Use as Conformational Constraints in Peptides", <i>J. Org. Chem.</i> , 47: pp. 104-109 (1982).
	Gaetzi, "Fungicidal Amino azacycloheptanones", <i>Chem. Abs.</i> , 66: 28690m.
	Games, et al., "Alzheimer-type Neuropathology In Transgenic Mice Overexpressing V717F $\beta$ -amyloid Precursor Protein", <i>Letters to Nature</i> , 373: pp. 523-527 (1995).
	Glennner, et al. "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein." <i>Biochem. Biophys. Res. Commun.</i> 120(3): 885-890 (1984).
	Goate, et al. "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease." <i>Letters to Nature</i> . 349: 704-706 (1991)
	Gracias, et al., "Efficient Nitrogen Ring-Expansion Process Facilitated by in Situ Hemiketal Formation", <i>J. Am. Chem. Soc.</i> , 117: pp. 8047-8048 (1995).
	Grunewald, et al., "Effect of Ring Size or an Additional Heteroatom on the Optency and Selectivity of Bicyclic Benzylamine-Type Inhibitors of Phenylethanolamine N-Methyltransferase", <i>J. Med. Chem.</i> , 39, pp. 3539 (1996).
	Hansen, et al., "Re-examination and further Development of a Precise and Rapid Dye Method for Measuring Cell Growth", <i>J. Immun. Meth.</i> , 119: pp. 203-210 (1989).
	Hart, et al., "The Ester Enolate-Imine Condensation Route to $\beta$ -Lactams", <i>Chem. Rev.</i> , 89: pp. 1447-1465 (1989).
	Herschmann, "Recherches sur la nature du Methonitrile de Wallach", <i>Helv. Chim. Acta</i> , 7:329, p. 2537-2547 (1949).

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO	ATTORNEY'S DKT NO.	APPLICATION NO.
	002010-586	09/916,440
	APPLICANT	
	Jing Wu, et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE	GROUP
	July 30, 2001	1624

	Hoffman, et al., "Efficient Synthesis of N-Substituted Lactams from (N-Arylsulfonyloxy) Amines and Cyclic Ketones", <i>Tetrahedron Letters</i> , 30: pp. 4207-4210 (1989).
	Hoffman, et al., "Synthesis and Structure of 7-Methyl-and 7-Pheynl-1,2,3,4-Tetrahydro-1,4-Diazepin-5-ones", <i>Tetrahydrodiazepinones.</i> , 27: p. 3565 (1962).
	Holladay, et al., "Synthesis of $\alpha$ -Benzyl $\gamma$ -Lactam, $\alpha$ -Benzyl $\delta$ -Lactam and $\alpha$ -Benzylproline Derivatives as Conformationally Restricted Analogues of Phenylalaninamide", <i>J. Org. Chem.</i> , 56: 3900-3905 (1991).
	Hu, et al., "Two Efficient Syntheses of (+)-anti-N-Benzyl-3-Amino-4-Hydroxyhexahydroazepine", <i>Tetrahedron Letters</i> , 36:21, pp. 3659-3662 (1995).
	Itoh, K., "Synthesis and Antiotensin Converting Enzyme-Inhibitory Activity of 1,5-benzothiazine...", <i>Chemical Abstracts</i> , Vol. 111, No. 15, 10/9/89, Columbus, OH, Astract No. 126464h.
	Johnson-Wood, et al. "Amyloid precursor protein processing and A $\beta$ <sub>42</sub> deposition in a transgenic mouse model of Alzheimer's disease." <i>PNAS USA</i> . 94: 1550-1555 (1997).
	Kawase, et al., "Electrophilic Aromatic Substitution with N-Methoxy-N-Acylnitrenium Ions Generated from N-Chloro-N-Methoxyamies", <i>J. Org. Chem.</i> , 54: pp. 3394-3403 (1989).
	King, et al., "Iodotrimthylsilane-Mediated 2-Mononhalogenation of 4-aza-5 $\alpha$ -androstan-3-one Steriods", <i>J. Org. Chem.</i> 58: pp. 3384 (1993).
	Kitagawa, et al., "Structural Aanlysis of $\beta$ -Turn Mimics Containing a Substituted 6-Aminocaproic Acid Linker", <i>J. Am. Chem. Soc.</i> , 117: pp. 5169-5178.
	Klolic, "Amino Acids and Peptides LXXXIX Synthesis of L-4-Azalsine, D-4-Azalsine, and L-4-Azalsine0[6-14C]" <i>Coll. Czech. Chem.Comm.</i> , 34, pp. 630 (1969).
	Kametani, et al., "A Simple Synthesis of 4-Thiazolidones, Tetrahydro-1,3-Thiazin-4-One and Hexahydro-1,3-Thiazepin-4-Ones from Amide-Thiols", <i>Heterocycles</i> , 9: pp. 831-840 (1978).
	Krimm, "Uber Isonitron", <i>Chem. Ber.</i> , 91: p. 1057 (1958).
	Krow, et al., "Regioselective Functionalization", <i>J. Org. Chem.</i> , 61: pp. 5574-5580 (1996).
	Ksander, G.M., et al. "Dual Angiotensin Converting Enzyme/Thromboxane Synthase Inhibitors.", <i>J. Med. Chem.</i> 37: 1823-1832 (1994).
	Kukolja, et al., "Orally Absorbable Cephalosporin Antibiotics", <i>J. Med. Chem.</i> , 28:12, pp. 1886 (1985).
	Losse, G., et al., "Synthese Des Depsipeptides Valinomycin", <i>Tetrahedron</i> , 27, pp. 1423-1434 (1971).

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO	ATTORNEY'S DKT NO. 002010-586	APPLICATION NO. 09/916,440
	APPLICANT Jing Wu, et al.	
	FILING DATE July 30, 2001	GROUP 1624
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	

	Lowe, et al., "5,7-Diphenyl-3-Ureidohexahydroazepin-2-Ones as Cholecystokinin-B Receptor Ligands", <i>Bioorg &amp; Med Chem Letters</i> , 4:24, pp. 2877-2882 (1994).
	McKennis, et al., "The Synthesis of Hydroxycotinine and Studies on Its Structure", <i>Synthesis and Hydroxycotinine</i> , pp. 383-387 (1963).
	Micouin, et al., "Asymmetric Synthesis", <i>Tetrahedron</i> , 52:22, pp. 7719-7726 (1996).
	Miller, et al., "Application of Ring-Closing Methathesis to the Synthesis of Rigidified Amino Acids and Peptides", <i>J. Am. Chem. Soc.</i> , 118, pp. 9606-9614 (1996).
	Mullan, et al., "A Pathogenic Mutation for Probable Alzheimer's Disease in the APP Gene at the N-Terminus of $\beta$ -Amyloid", <i>Nature Genetics</i> 1, pp. 345-347 (1992).
	Murrell, et al., "A Mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease", <i>Reports</i> , pp. 97-99 (1991).
	Nedenskov, et al., "Synthesis of Potential Hypnotics", <i>Acta. Chem. Scand.</i> , 12:7, pp. 1404-1410 (1958).
	Ogliaruso and wolfe, <i>Synthesis of Lactones and Lactams</i> , Patai, et al., Ed., J. Wiley & Sons, NY:NY, (1993).
	Orito, et al., "Benzolactams-1", <i>Tetrahedron</i> , 36:8, pp. 1017-1021 (1980).
	Overberger, et al., "Optically Active Polyamides", <i>Brooklyn Polytechnic</i> , pp. 3431-3435 (1963).
	Overberger et al., "The Synthesis of Optically Active C-Methyl-2-oxoheptamethyleminines and C-Methyl-7-aminoheptanoic Acids", <i>Macromolecules</i> , 1:1, pp. 1-6 (1968)
	Parsons, et al., "Benzolactams. A New Class of Converting Enzyme Inhibitors", <i>Biochem. Biophys. Res. Comm.</i> , 117: pp. 108-113 (1983).
	Pedersen, et al., "Studies on Organophosphorus Compounds", <i>Tetrahedron</i> , 35: p. 2433 (1979).
	Reupple, et al., "Abberant Alkaloid Biosynthesis", <i>J. Am. Chem. Soc.</i> , 93: 7021 et seq. (1971).
	Robl, et al., "Synthesis of Benzo-Fused, 7,5-and 7,6-Fused Azepinones and Conformationally Restricted Dipeptide Mimetics", <i>Tetrahedron Lett.</i> , 36:10, pp. 1593-1596 (1995).
	Robl, et al., "Dual Metalloprotease Ihibitors", <i>Bioorg. Med. Che. Letter</i> , 4: pp. 1789-1794 (1994).
	Rodriguez, et al., "Conformationally Restricted Analogues of Methionine", <i>Tetrahedron</i> , 52: pp. 7727-7736 (1996).

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO	ATTORNEY'S DKT NO.	APPLICATION NO.
	002010-586	09/916,440
	APPLICANT	
	Jing Wu, et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE	GROUP
	July 30, 2001	1624

	Sekakida, et al., "Studies on Seven-membered Heterocyclic Compounds Containing Nitrogen", <i>Bull. Chem. Soc. Japan</i> , 44: pp. 478-480 (1971).
	Selkoe, et al. "Amyloid Protein and Alzheimer's Disease." <i>Scientific American</i> . 68-78 (1991).
	Selkoe, et al. "The Molecular Pathology of Alzheimer's Disease." <i>Neuron</i> . 6:487-498 (1991).
	Shirota, et al., "Potential Inhibitors of Collagen Biosynthesis", <i>J. Med. Chem.</i> , 20: pp. 1623-1627 (1977).
	Skiles, et al., "Eleastase Inhibitors Containing Conformationally Restricted Lactams", <i>Bioorg. Med. Chem. Letter</i> , 3: pp. 773-778 (1993).
	Slusarchyk, et al., "Dual Metalloprotease Inhibitors.V.", <i>Bioorg. med. Chem. Lett.</i> , 5: pp. 753-758 (1995).
	Smith, et al., "The Curtius Reaction", <i>Organic Reactions</i> , Ch. 9, pp. 337-449 (1946).
	Suda, et al., "Metalloporphyrin-catalysed Rearrangement of Oxaziridines", <i>J. Chem. Soc. Chem. Comm.</i> , pp. 949-950 (1994).
	Thomas, et al, "Nuclear Magnetic Resonance Studies and Conformational Analysis of Bicyclic Inhibitors of Angiotensin-converting Enzyme", <i>J. Chem. Soc. Perkin II</i> , 747 (1986).
	Ugi, et al., "Ugi Reactions with Trifunctional $\alpha$ -Amino Acids, Aldehydes, Isocyanides and Alcohols", <i>Tetrahedron</i> , 52:35, pp. 11657-11664 (1996).
	Van der Steen, et al., "Synthesis of 3-Amino-2-Azetidinones: A Literature Survey", <i>Tetrahedron Letters</i> , 47: pp. 7503-7524 (1991).
	Vedejs, et al., "Synthesis of N-Methoxy and N-H Aziridines from Alenes", <i>Tetrahedron Letters</i> , 33: pp. 3261-3264 (1992).
	Wada, et al., "Stereospecific and Stereoselective Reactions", <i>Bull. Chem. Soc. Japan</i> , 46: pp. 2833-2835 (1973).
	Wasserman, et al., "Total Synthesis of ( $\pm$ )-Dihydroperiphylline", <i>J. Am. Chem. Soc.</i> , 103, p. 461-462 (1981).
	Wattley, et al., "Synthesis and Biological Properties of (Carboxyalkyl)amino-Substituted Bicyclic Lactam Inhibitors of Angiotensin converting Enzyme", <i>J. Med. Chem.</i> , 28: pp. 1511-1516 (1985).

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	ATTORNEY'S DKT NO. 002010-586	APPLICATION NO. 09/916,440
	APPLICANT Jing Wu, et al.	
	FILING DATE July 30, 2001	GROUP 1624

	Wheeler, et al., "Formation and Photochemical Wolff Rearrangement of Cyclic $\alpha$ -Diazo Ketones", <i>Organic Syntheses</i> , Coll. Vol. VI, p. 840.		
	Wolff, "The Schmidt Reaction", <i>Organic Reactions</i> , ch. 8, pp. 307-336 (1946).		
	Yakoo, et al., "Studies on Seven-Membered Heterocyclic Compounds Containing Nitrogen", <i>Bull. Chem. Soc. Japan</i> , 29: p. 631 (1956).		
	Yanganasawa, et al., "Angiotensin-converting Enzyme Inhibitors", <i>J. Med. Chem.</i> , 30: p. 1984-1991 (1987).		
Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of	)	
Jing Wu, et al.	)	Group Art Unit: 1624
Application No.: 09/916,440	)	Examiner: B. Kifle
Filed: July 30, 1997	)	
For: CYCLOALKYL, LACTAM, LACTONE	)	
AND RELATED COMPOUNDS,	)	
PHARMACEUTICAL COMPOSITIONS	)	
COMPRISING SAME, AND METHODS	)	
FOR INHIBITING $\beta$ -AMYLOID	)	
PEPTIDE RELEASE AND/OR ITS	)	
SYNTHESIS BY USE OF SUCH	)	
COMPOUNDS	)	

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**TRANSMITTAL LETTER**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Enclosed is a Supplemental Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☐ No additional fee for submission of an IDS is required.
- ☒ The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.97(p) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \$\_\_\_\_\_ to Deposit Account No. 02-4800 for the fee due.
- ☒ A check in the amount of \$ 180.00 is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: 5-2-02  
P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(650)622-2300

By: Gerald F. Swiss  
Gerald F. Swiss  
Registration No. 30,113



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of )  
Jing Wu, et al. ) Group Art Unit: 1624  
Application No.: 09/916,440 ) Examiner: B. Kifle  
Filed: July 30, 2001 )  
For: CYCLOALKYL, LACTAM, LACTONE )  
AND RELATED COMPOUNDS, )  
PHARMACEUTICAL COMPOSITIONS )  
COMPRISING SAME, AND METHODS )  
FOR INHIBITING  $\beta$ -AMYLOID )  
PEPTIDE RELEASE AND/OR ITS )  
SYNTHESIS BY USE OF SUCH )  
COMPOUNDS )

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited below is enclosed.

**U.S. Patents**

1.	3,657,341	Thorne, et al.	April 18, 1972
2.	4,410,520	Watthey	October 18, 1983
3.	4,473,575	Watthey	September 25, 1984
4.	5,015,639	Berger et al.	May 14, 1991
5.	5,206,235	Fisher et al.	April 27, 1993
6.	5,247,080	Berger et al.	September 21, 1993
7.	5,486,541	Sterling et al.	January 23, 1996
8.	5,502,048	Chapdelaine et al.	March 26, 1996

9.	5,519,061	Youdim et al.	May 21, 1996
10.	5,532,415	Youdim et al.	July 2, 1996
11.	5,656,626	Chapdelaine et al.	August 12, 1997
12.	5,672,598	De et al.	September 30, 1997

**Foreign Patents**

13.	EP 0 732 399	9/18/96
14.	GB 1 519 931	1/6/77

**Articles**

15. Semple, et al., "Design, Synthesis and Evolution of a Novel, Selective, and Orally Bioavailable Class of Thrombin Inhibitors: P1-Argininal Derivatives Incorporating P3-P4 Lactam Sulfonamides Moieties", *J. Med. Chem.*, Vol. 39, pp. 4531-4536, (1996).

A fee in the amount of \$180.00 (126) is enclosed in conformance with 37 C.F.R.

§ 1.97(c). To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: 5-2-02

By:

Gerald F. Swiss  
Gerald F. Swiss  
Registration No. 30,113

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(650) 622-2300

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	ATTORNEY'S DKT NO. 002010-586	APPLICATION NO. 09/916,440
	APPLICANT Jing Wu, et al.	
	FILING DATE July 30, 2001	GROUP 1624

U.S. PATENT DOCUMENTS						
Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)		
	Number	Kind Code (if known)				
	3,657,341		Thorne, et al.	4/18/72		
	4,410,520		Wattthey	10/18/83		
	4,473,575		Wattthey	9/25/84		
	5,015,639		Berger et al.	5/14/91		
	5,206,235		Fisher et al.	4/27/93		
	5,247,080		Berger et al.	9/21/93		
	5,486,541		Sterling et al.	1/23/96		
	5,502,048		Chapdelaine et al.	3/26/96		
	5,519,061		Youdim et al.	5/21/96		
	5,532,415		Youdim et al.	7/2/96		
	5,656,626		Chapdelaine et al.	8/12/97		
	5,672,598		De et al.	9/30/97		
FOREIGN PATENT DOCUMENTS						
Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	no
	EP 0 732 399		Europe	9/18/96		
	GB 1 519 931		UK	1/6/77		
NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	Semple, et al., "Design, Synthesis and Evolution of a Novel, Selective, and Orally Bioavailable Class of Thrombin Inhibitors: P1-Argininal Derivatives Incorporating P3-P4 Lactam Sulfonamides Moieties", <i>J. Med. Chem.</i> , Vol. 39, pp. 4531-4536, (1996).					
Examiner Signature			Date Considered			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of	)	
Jing Wu, et al.	)	Group Art Unit: 1624
Application No.: 09/916,440	)	Examiner: B. Kifle
Filed: July 30, 2001	)	
For: CYCLOALKYL, LACTAM, LACTONE	)	
AND RELATED COMPOUNDS,	)	
PHARMACEUTICAL COMPOSITIONS	)	
COMPRISING SAME, AND METHODS	)	
FOR INHIBITING $\beta$ -AMYLOID	)	
PEPTIDE RELEASE AND/OR ITS	)	
SYNTHESIS BY USE OF SUCH	)	
COMPOUNDS	)	

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**TRANSMITTAL LETTER**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Enclosed is a Supplemental Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \$\_\_\_\_\_ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of \$\_\_\_\_\_ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: 2/6/08  
P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(650)622-2300

By: Lawrence S. Squires  
Lawrence S. Squires  
Registration No. 24,060

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of )  
)  
Jing Wu, et al. ) Group Art Unit: 1624  
)  
Application No.: 09/916,440 ) Examiner: B. Kifle  
)  
Filed: July 30, 2001 )  
)  
For: CYCLOALKYL, LACTAM, LACTONE )  
AND RELATED COMPOSITIONS )  
COMPRISING SAME, AND METHODS )  
FOR INHIBITING  $\beta$ -AMYLOID )  
PEPTIDE RELEASE AND/OR ITS )  
SYNTHESIS BY USE OF SUCH )  
COMPOUNDS )

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited below is enclosed.

**U.S. Patents**

1.	4,410,520	Watthey	October 18, 1983
2.	4,473,575	Watthey	September 24, 1984
3.	5,015,639	Berger et al.	May 14, 1991
4.	5,206,235	Fisher et al.	April 27, 1993
5.	5,247,080	Berger et al.	September 21, 1993
6.	5,486,541	Sterling et al.	January 23, 1996
7.	5,502,048	Chapdelaire et al.	March 26, 1996
8.	5,519,061	Youdim et al.	May 21, 1996

9.	5,532,415	Youdim et al.	July 2, 1996
10.	5,656,626	Chapdelaine et al.	August 12, 1997
11.	5,672,598	De et al.	September 30, 1997


The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b). In the event that an Office Action is mailed prior to receipt of this paper, the Commissioner is hereby authorized to charge the requisite fees to Deposit Account No. 02-4800.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: 2/6/02

By:   
Lawrence S. Squires  
Registration No. 24,060

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(650) 622-2300

APPLICATION No.  
09/916.440

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**FILING DATE**  
July 30, 2001

Gr up  
1624

## U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		
	4,410,520		Wattthey	10/18/83
	4,473,575		Wattthey	9/24/84
	5,015,639		Berger et al.	5/14/91
	5,206,235		Fisher et al.	4/27/93
	5,247,080		Berger et al.	9/21/93
	5,486,541		Sterling et al.	1/23/96
	5,502,048		Chapdelaire et al.	3/26/96
	5,519,061		Youdim et al.	5/21/96
	5,532,415		Youdim et al.	7/2/96
	5,656,626		Chapdelaine et al.	8/12/97
	5,672,598		De et al.	9/30/97

## FOREIGN PATENT DOCUMENTS

Foreign Patent Documents						
Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	no

## NON PATENT LITERATURE DOCUMENTS

LITERATURE DOCUMENTS			
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
Examiner Signature		Date Considered	

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **SEND TO:** Assistant Commissioner for Patents, Washington, D.C. 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of	)	
	)	
Jing Wu, et al.	)	Group Art Unit: Unassigned
	)	
Application No.: Unassigned	)	Examiner: Unassigned
	)	
Filed: ON EVEN DATE HEREWITH	)	
	)	
For: CYCLOALKYL, LACTAM, LACTONE	)	
AND RELATED COMPOUNDS,	)	
PHARMACEUTICAL COMPOSITIONS	)	
COMPRISING SAME, AND METHODS	)	
FOR INHIBITING $\beta$ -AMYLOID	)	
PEPTIDE RELEASE AND/OR ITS	)	
SYNTHESIS BY USE OF SUCH	)	
COMPOUNDS	)	

**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. §1.98, a copy of each of the following documents was submitted in Application No. 08/996,422, upon which is based a claim for priority under 35 U.S.C. §120.

1. U.S. Patent No. 3,657,341, issued April 18, 1972, to Thorne.
2. U.S. Patent No. 4,477,464, issued October 16, 1984, Slade, et al.
3. U.S. Patent No. 4,666,829, issued May 19, 1987, to Glenner, et al.
4. U.S. Patent No. 4,977,168, issued December 11, 1990, to Bernat, et al.
5. U.S. Patent No. 5,238,932, issued August 24, 1993, to Flynn, et al.
6. U.S. Patent No. 5,283,241, issued February 1, 1994, to Bochis, et al.
7. U.S. Patent No. 5,284,841, issued February 8, 1994, to Chu, et al.
8. U.S. Patent No. 5,324,726, issued June 28, 1994, to Bock, et al.
9. U.S. Patent No. 5,360,802, issued November 1, 1994, to Chambers, et al.



10. U.S. Patent No. 5,420,271, issued May 30, 1995, to Warchawsky, et al.
11. U.S. Patent No. 5,556,969, issued September 17, 1996, to Chambers, et al.
12. U.S. Patent No. 5,633,251, issued May 27, 1997, to Claremon, et al.
13. U.S. Patent No. 5,658,901, issued August 19, 1997, to Claremon, et al.
14. U.S. Patent No. 5,712,397, issued January 27, 1998, to Esser, et al.
15. U.S. Patent No. 5,770,573, issued June 23, 1998, to Arrhenius, et al.
16. Canadian Patent No. 1 063 108, published September 25, 1979.
17. European Patent No. 0 167 919, published January 15, 1986.
18. European Patent No. 0 284 256, published September 28, 1988.
19. European Patent No. 0 349 949, published January 10, 1990.
20. European Patent No. 0 376 849, published July 4, 1990. (Abstract in English)
21. European Patent No. 0 434 360, published June 26, 1991.
22. European Patent No. 0 434 364, published June 26, 1991.
23. European Patent No. 0 434 369, published June 26, 1991.
24. European Patent No. 0 490 590, published June 17, 1992.
25. European Patent No. 0 514 133, published November 19, 1992.
26. European Patent No. 0 523 845, published January 20, 1993.
27. European Patent No. 0 549 039, published June 30, 1993.
28. European Patent No. 0 647 632, published April 12, 1995.
29. European Patent No. 0 652 009 A1, published June 10, 1995.
30. European Patent No. 0 667 344, published August 16, 1995.
31. European Patent No. 0 677 517 A1, published October 18, 1995.
32. European Patent No. 0 732 399 A, published September 18, 1996.
33. European Patent No. 0 778 266 A1, published November 6, 1997.
34. GB 1 519 495, published July 6, 1978.
35. GB 1 573 931, published August 18, 1980.
36. GB 2 272 439, published May 18, 1994.
37. GB 2 290 788 A, published January 10, 1996.
38. JP 04210967 A2, published August 3, 1994.
39. JP 06145148 A2, published May 24, 1994.

40. JP 07304770 A2, published November 21, 1995.
41. JP 10072444 A2, published March 17, 1998.
42. International Publication No. WO 92/01683, published February 6, 1992.
43. International Publication No. WO 92/16524, published October 1, 1992.
44. International Publication No. WO 93/19052, published September 30, 1993.
45. International Publication No. WO 93/19063, published September 30, 1993.
46. International Publication No. WO 94/05693, published March 17, 1994.
47. International Publication No. WO 94/04531, published March 3, 1994.
48. International Publication No. WO 94/07486, published April 14, 1994.
49. International Publication No. WO 94/10569, published May 11, 1994.
50. International Publication No. WO 95/03289, published February 2, 1995.
51. International Publication No. WO 95/03290, published February 2, 1995.
52. International Publication No. WO 95/09838, published April 13, 1995.
53. International Publication No. WO 95/14671, published June 1, 1995.
54. International Publication No. WO 95/21840, published August 17, 1995.
55. International Publication No. WO 95/23810, published September 8, 1995.
56. International Publication No. WO 95/25118, published September 21, 1995.
57. International Publication No. WO 95/32191, published November 30, 1995.
58. International Publication No. WO 96/05839, published February 29, 1996.
59. International Publication No. WO 96/16981, published June 6, 1996.
60. International Publication No. WO 96/19492, published June 27, 1996.
61. International Publication No. WO 96/20725, published July 11, 1996.
62. International Publication No. WO 96/22966, published August 1, 1996.
63. International Publication No. WO 96/40146, published December 19, 1996.
64. International Publication No. WO 96/40653, published December 19, 1996.
65. International Publication No. WO 96/40654, published December 19, 1996.
66. International Publication No. WO 96/40655, published December 19, 1996.
67. International Publication No. WO 96/40656, published December 19, 1996.
68. International Publication No. WO 97/30072, published August 21, 1997.
69. International Publication No. WO 97/38705, published October 23, 1997.

70. International Publication No. WO 98/00405, published January 8, 1998.
71. International Publication No. WO 98/25930, published June 18, 1998.
72. International Publication No. WO 98/28268, published July 2, 1998.
73. International Publication No. WO 98/38177, published September 3, 1998.
74. Aquino, et al. "Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity. 1. Optimization of the Agonist "Trigger." *J. Med. Chem.* 39: 562-569 (1996).
75. Arienti, et al. "Regioselective Electrophilic Alkylation of Anilines with Phanylacetylene in the Presence of Montmorillonite KSF." *Tetrahedron* 53(10): 3795-3804 (1997).
76. Bock, et al. "Synthesis and Resolution of 3-Amino-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones." *J. Org. Chem.* 52: 3232-3239 (1987).
77. Bock, et al. "An Expedient Synthesis of 3-Amino-1,3-Dihydro-5-Phenyl-2H-1,4-Benzodiazepin-2-one." *Tet. Lett.* 28(9): 939-942 (1987).
78. Bock, et al. "Selective Non-Peptide Ligands for an Accommodating Peptide Receptor. Imidazobenzodiazepines as Potent Cholecystokinin Type B Receptor Antagonists." *Bioorg. and Med. Chem. Lett.* 2(9):987-998 (1994).
79. Brown, et al. "A Revision of the structure of "7-Phenyloxindole"; Photochemical Synthesis and Pyrolytic Behaviour of Authentic 7-Phenyloxindole." *Tet. Lett.* 8: 667-670 (1971).
80. Chambers, et al. L-708,474: the C5-Cyclohexyl Analogue of L-365,260, A Selective High Affinity Ligand for the CCKB/Gastrin Receptor." *Bioorg. and Med. Chem. Lett.* 3(10):1919-1924 (1993).
81. Cordell. "B-Amyloid Formation as a Potential Therapeutic Target for Alzheimer's Disease." *Ann. Rev. Pharmacol. Toxicol.* 34:69-89 (1994).
82. Evans, , et al. "Assymetric Synthesis of -Amino Acids, Electrophilic Azidation of Chiral Imide Enolates, a Practical Approach to the Synthesis of (R)- and (S)- Azido Carboxylic Acids." *J. Am. Chem. Soc.* 112: 4011-1030.
83. Evans, et al. "Methods for Drug Discovery: Development of Potent, Selective Orally Effective Cholecystokinin Antagonists." *J. Med. Chem.* 31:2235-2246 (1988).

84. Evans, et al. "Molecular Mimicry and the Design of Peptidomimetics." *Molecular Mimicry in Health and Disease*. (A. Lernmark, et al., eds.) Elsevier Science Publishers B.v. (Biomedical Division) (1988) pp. 23-34.
85. Finizia, et al. "Synthesis and Evaluation of Novel 1,5-Benzodiazepines as potent and selective CCK-B Ligands, Effect of the Substitution of the N-5 Phenyl with Alkyl Groups." *Bioorg. & Medicinal Chemistry Letters*. 6(24):2957-2962 (1996).
86. Hirst, et al. "Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonists Activity (II): Optimization of the C3 Amino Substituent." *J. Med. Chem.* 39: 5236-5245 (1996).
87. Hofmann, et al. "Interactions of Benzodiazepine Derivatives with Annexins." *J. Biol. Chem.* 273(5):2885-2894 (1998).
88. Katrizky, et al. "Benzodiazepine Derivatives with Annexins." *J. Biol. Chem.* 273(5): 2885-2894 (1998).
89. Lowe, et al. "A Water Soluble Benzazepine Cholecystokinin-B-Receptor Antagonist." *Bioorg. and Med. Chem. Lets.* 5(17): 1933-1936 (1995).
90. Lowe, et al. "5-Phenyl-3-ureidobenzazepin-2-ones as Cholecystokinin-B Receptor Antagonists." *J. Med. Chem.* 37: 3789-3811 (1994).
91. Milligan, et al. "Intramolecular Schmidt Reactions of Alkyl Azides with Ketones: Scope and Stereochemical Studies." *J. Am. Chem. Soc.* 117: 10449-10459 (1995).
92. Papadopoulos, et al. "Anodic Oxidation of N-Acyl and N-Alkoxy carbonyl Dipeptide Esters as a Key Step for the Formation of Chiral Heterocyclic Synthetic Building Blocks." *Tetrahedron* 47(4/5):563-572 (1991).
93. Patel, et al. "Biological Properties of the Benzodiazepine Amidine Derivative L-740,093, a Cholecystokinin-B/Gastrin Receptor Antagonist with High Affinity in vitro and High Potency in vivo." *Molecular Pharmacology*. 46:943-948 (1994).
94. Reiter, et al. "Crystallization-Induced Asymmetric Transformation: Stereospecific Synthesis of a Potent Peripheral CCK Antagonist." *J. Org. Chem.* 52: 955-957 (1987).
95. Rittle, et al. "A New Amine Resolution Method and its Application to 3-Aminobenzodiazepines." *Tet. Lets.* 28(5):521-522 (1987).
96. Robl. "Synthesis of 2-(4-Fluorophenyl)-4-isopropyl-3-quinolinecarbaldehyde: A New Route to 2,3,4-Substituted Quinolines." *Synthesis*. 56-58 (1991).

97. Satoh, et al. "New 1,4-Benzodiazepine-2-one Derivatives as Gastrin/Cholecystokinin-B Antagonists." *Chem. Pharm. Bull.* 43(12): 2159-2167 (1995).
98. Satyanarayana, et al. "Carbonylation of Benzyl Halides Using  $\text{CoCl}_2/\text{NaBH}_4/\text{CO}/\text{NaOH}$  Reagent System." *Tet. Lets.* 28(23): 2633-2636 (1987).
99. Semple, et al. "Design, Synthesis, and Evolution of a Novel, Selective, and Orally Bioavailable Class of Thrombin Inhibitors: P1-Argininal Derivatives Incorporating P3-P4 Lactam Sulfoamide Moieties." *J. Med. Chem.* 39: 4531-4536 (1996).
100. Sherrill, et al. "An Improved Synthesis and Resolution of 3-Amino-1,3 dihydro-5-phenyl-2H-1,4-benzodiazepinn-2-ones." *J. Org. Chem.* 60:730-734 (1995).
101. Showell, et al. "High Affinity and Potent, Water-Soluble 5-Amino-1,4-Benzodiazepine CCKB/Gastrin Receptor Antagonists Containing a Cationic Solubilizing Group." *J. Med. Chem.* 37:719-721 (1994).
102. Smith, et al. " $\beta$ -APP Processing as a Therapeutic Target for Alzheimer's Disease." *Current Pharmaceutical Design.* 3:439-445 (1997).
103. Stewart. "Syntheses of L-Kynurenine Peptides Conducted Without Masking the Side-Chain Amino Group." *Aust. J. Chem.* 33: 633-640 (1980).
104. Van Niel, et al. "CCKB Selective Receptor Ligands: Novel 1,3,5-Trisubstituted Benzazepin-2-ones." *Bioorganic & Medicinal Chemistry Letters.* 5(13):1421-1426 (1995).
105. Varnavas, et al. "Synthesis of New Benzodiazepine Derivatives as Potential Cholecystokinin Antagonists." *Il Farmaco.* 46(2):391-401 (1991).
106. Waldmann, et al. "Selective Enzymatic Removal of Protecting Groups: The Phenylacetamide as Amino Protecting Group in Phosphopeptide Synthesis." *Tet. Lets.* 37(48): 8725-8728 (1996).
107. Warshawsky, et al. "The Synthesis of Aminobenzazepinones as Anti-Phenylalanine Dipeptide Mimics and Their Use in NEP Inhibition." *Bioorg. & Med. Chem. Lets.* 6(8): 957-962 (1996).
108. Zoller, et al. "Aminoalkylation of Cerebratins with Glyoxylic Acid Derivatives." *Tetrahedron.* 31: 863-866 (1973).

The documents are being submitted before the first Office Action on the merits, therefore no fee or certification is required under 37 C.F.R. § 1.97(b). In the event that an Office Action is mailed prior to receipt of this paper, the Commissioner is hereby authorized to charge the requisite fees under 37 C.F.R. § 1.97(c) for submission of this paper to Deposit Account No. 02-4800.

By citing the above references, Applicants do not acquiesce or admit that any of these documents are "prior art" under 35 U.S.C. Applicants specifically reserve the right, where appropriate, to antedate any of the cited documents by an appropriate showing under 37 C.F.R. §1.131, §1.604, §1.608 or any other suitable means.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: Lawrence S. Squires  
Lawrence S. Squires  
Registration No. 24,060

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(650)622-2300

Date: July 26, 2001

<b>INFORMATION DISCLOSURE CITATION</b>  PTO-1449				ATTORNEY'S DKT NO. 002010-586		APPLICATION NO. Unassigned	
				APPLICANT Jing Wu, et al.			
				FILING DATE Filed Herewith.		GROUP Unassigned	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	3,657,341	4/18/72	Thorne, et al.				
	4,080,449	3/21/78	Croissier, et al.				
	4,477,464	10/16/84	Slade, et al.				
	4,666,829	5/19/87	Glennner, et al.				
	4,977,168	12/11/90	Bernat, et al.				
	5,238,932	8/24/93	Flynn, et al.				
	5,283,241	2/8/94	Bochis, et al.				
	5,284,841	2/8/94	Chu, et al.				
	5,324,726	6/28/94	Bock, et al.				
	5,360,802	11/1/94	Chambers, et al.				
	5,420,271	5/30/95	Warchawsky, et al.				
	5,556,969	9/17/96	Chambers, et al.				
	5,633,251	5/27/97	Claremon, et al.				
	5,658,901	8/19/97	Claremon, et al.				
	5,712,397	1/27/98	Esser, et al.				
	5,770,573	6/23/98	Arrhenius, et al.				
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
	1 063 108	9/25/79	Canada				
	0 167 919	1/15/86	Europe				
	0 284 256	9/28/88	Europe				
	0 349 949	1/10/90	Europe				

INFORMATION DISCLOSURE CITATION  PTO-1449				ATTORNEY'S DKT NO. 002010-586		APPLICATION NO. Unassigned	
				APPLICANT Jing Wu, et al.			
				FILING DATE Filed Herewith		GROUP Unassigned	
	0 376 849	7/4/90	Europe				
	0 434 360	6/26/91	Europe				
	0 434 364	6/26/91	Europe				
	0 434 369	6/26/91	Europe				
	0 490 590	6/17/92	Europe				
	0 514 133	11/19/92	Europe				
	0 523 845	1/20/93	Europe				
	0 549 039	6/30/93	Europe				
	0 647 632	4/12/95	Europe				
	0 652 009	6/10/95	Europe				
	0 667 344	8/16/95	Europe				
	0 677 517	10/18/95	Europe				
	0 732 399	9/18/96	Europe				
	0 778 266	11/6/97	Europe				
	1 519 931	7/6/78	Great Britain				
	1 573 931	8/18/80	Great Britain				
	2 272 439	5/18/94	Great Britain				
	2 290 788	1/10/96	Great Britain				
	04210967	8/3/94	Japan				
	06145148	5/24/94	Japan				
	07304770	11/21/95	Japan				
	10072444	3/17/98	Japan				
	92/01683	2/6/92	WIPO				
	92/16524	10/1/92	WIPO				
	93/19052	9/30/93	WIPO				
	93/19063	9/30/93	WIPO				
	94/05693	3/17/94	WIPO				
	94/04531	3/3/94	WIPO				
	94/07486	4/14/94	WIPO				
	94/10569	5/11/94	WIPO				



<b>INFORMATION DISCLOSURE CITATION</b>  <b>PTO-1449</b>				ATTORNEY'S DKT NO. 002010-586		APPLICATION NO. Unassigned	
				APPLICANT Jing Wu, et al.			
				FILING DATE Filed Herewith		GROUP Unassigned	
	95/03289	2/2/95	WIPO				
	95/03290	2/2/90	WIPO				
	95/09838	4/13/95	WIPO				
	95/14671	6/1/95	WIPO				
	95/21840	8/17/95	WIPO				
	95/23810	9/8/95	WIPO				
	95/25118	9/21/95	WIPO				
	95/32191	11/30/95	WIPO				
	96/05839	2/29/96	WIPO				
	96/16981	6/6/96	WIPO				
	96/19492	6/27/96	WIPO				
	96/20725	7/11/96	WIPO				
	96/22966	8/1/96	WIPO				
	96/40146	12/19/96	WIPO				
	96/40653	12/19/96	WIPO				
	96/40654	12/19/96	WIPO				
	96/40655	12/19/96	WIPO				
	96/40656	12/19/96	WIPO				
	97/30072	8/21/97	WIPO				
	97/38705	10/23/97	WIPO				
	98/00405	1/8/98	WIPO				
	98/25930	6/18/98	WIPO				
	98/28268	7/2/98	WIPO				
	98/38177	9/3/98	WIPO				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Aquino, et al. "Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity. 1. Optimization of the Agonist "Trigger." <i>J. Med. Chem.</i> 39: 562-569 (1996).						

<b>INFORMATION DISCLOSURE CITATION</b>  <b>PTO-1449</b>	ATTORNEY'S DKT NO. 002010-586	APPLICATION NO. Unassigned
	APPLICANT Jing Wu, et al.	
	FILING DATE Filed Herewith	GROUP Unassigned
	Arienti, et al. "Regioselective Electrophilic Alkylation of Anilines with Phanylacetylene in the Presence of Montmorillonite KSF." <i>Tetrahedron</i> 53(10): 3795-3804 (1997).	
	Bock, et al. "Synthesis and Resolution of 3-Amino-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones." <i>J. Org. Chem.</i> 52: 3232-3239 (1987).	
	Bock, e tal. "An Expedient Synthesis of 3-Amino-1,3-Dihydro-5-Phenyl-2H-1,4-Benzodiazepin-2-one." <i>Tet. Lets.</i> 28(9): 939-942 (1987).	
	Bock, et al. "Selective Non-Peptide Ligands for an Accommodating Peptide Receptor. Imidazobenzodiazepines as Potent Cholecystokinin Type B Receptor Antagonists." <i>Bioorg. and Med. Chem. Lets.</i> 2(9):987-998 (1994).	
	Brown, et al. "A Revision of the structureof "7-Phenyloxindole"; Photochemical Synthesis and Pyrolytic Behaviour of Authentic 7-Phenyloxindole." <i>Tet. Lets.</i> 8: 667-670 (1971).	
	Chambers, et al. L-708,474: the C5-Cyclohexyl Analogue of L-365,260, A Selective High Affinity Ligand for the CCKB/Gastrin Receptor." <i>Bioorg. and Med. Chem. Letts.</i> 3(10):1919-1924 (1993).	
	Cordell. "B-Amyloid Formation as a Potential Therapeutic Target for Alzheimer's Disease." <i>Ann. Rev. Pharmacol. Toxicol.</i> 34:69-89 (1994).	
	Evans, et al. "Methods for Drug Discovery: Development of Potent, Selective Orally Effective Cholecystokinin Antagonists." <i>J. Med. Chem.</i> 31:2235-2246 (1988).	
	Evans, et al. "Molecular Mimicry and the Design of Peptidomimetics." <i>Molecular Mimicry in Health and Disease.</i> (A. Lernmark, et al., eds.) Elsevier Science Publishers B.v. (Biomedical Division) (1988) pp. 23-34.	
	Finizia, et al. "Synthesis and Evaluation of Novel 1,5-Benzodiazepines as potent and selective CCK-B Ligands, Effect of the Substitution of the N-5 Phenyl with Alkyl Groups." <i>Bioorg. &amp; Medicinal Chemistry Letters.</i> 6(24):2957-2962 (1996).	
	Hirst, et al. "Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonists Activity (II): Optimization of the C3 Amino Substituent." <i>J. Med. Chem.</i> 39: 5236-5245 (1996).	
	Hofmann, et al. "Interactions of Benzodiazepine Derivatives with Annexins." <i>J. Biol. Chem.</i> 273(5):2885-2894 (1998).	
	Katrizky, et al. "Benzodiazepine Derivatives with Annexins." <i>J. Biol. Chem.</i> 273(5): 2885-2894 (1998).	
	Lowe, et al. "A Water Soluble Benzazepine Cholecystokinin-B-Receptor Antagonist." <i>Bioorg. and Med. Chem. Lets.</i> 5(17): 1933-1936 (1995).	
	Lowe, et al. "5-Phenyl-3-ureidobenzazepin-2-ones as Cholecystokinin-B Receptor Antagonists." <i>J. Med. Chem.</i> 37: 3789-3811 (1994).	
	Milligan, eet al. "Intramolecular Schmidt Reactions of Alkyl Azides with Ketones: Scope and Stereochemical Studies." <i>J. Am. Chem. Soc.</i> 117: 10449-10459 (1995).	
	Papadopoulos, et al. Anodic Oxidation of N-Acyl and N-Alkoxy carbonyl Dipeptide Esters as a Key Steop for the Formation of Chiral Heterocyclic Synthetic Building Blocks." <i>Tetrahedron</i> 47(4/5):563-572 (1991).	
	Patel, et al. "Biological Preperities of the Benzodiazepine Amidine Derivative L-740,093, a Choleycystokinin-B/Gastrin Receptor Antagonist with High Affinity in vitro and High Potency in vivo." <i>Molecular Pharmacology.</i> 46:943-948 (1994).	

<b>INFORMATION DISCLOSURE CITATION</b>  PTO-1449		ATTORNEY'S DKT NO. 002010-586	APPLICATION NO. Unassigned
		APPLICANT Jing Wu, et al.	
		FILING DATE Filed Herewith	GROUP Unassigned
	Reiter, et al. "Crystallization-Induced Asymmetric Transformation: Stereospecific Synthesis of a Potent Peripheral CCK Antagonist." <i>J. Org. Chem.</i> 52: 955-957 (1987).		
	Rittle, et al. "A New Amine Resolution Method and its Application to 3-Aminobenzodiazepines." <i>Tet. Lets.</i> 28(5):521-522 (1987).		
	Robl. "Synthesis of 2-(4-Fluorophenyl)-4-isopropyl-3-quinolinecarbaldehyde: A New Route to 2,3,4-Substituted Quinolines." <i>Synthesis.</i> 56-58 (1991).		
	Satoh, et al. "New 1,4-Benzodiazepine-2-one Derivatives as Gastrin/ Cholecystokinin-B Antagonists." <i>Chem. Pharm. Bull.</i> 43(12): 2159-2167 (1995).		
	Satyanarayana, et al. "Carbonylation of Benzyl Halides Using CoCl <sub>2</sub> /NaBH <sub>4</sub> /CO/NaOH Reagent System." <i>Tet. Lets.</i> 28(23): 2633-2636 (1987).		
	Semple, et al. "Design, Synthesis, and Evolution of a Novel, Selective, and Orally Bioavailable Class of Thrombin Inhibitors: P1-Argininal Derivatives Incorporating P3-P4 Lactam Sulfoamide Moieties." <i>J. Med. Chem.</i> 39: 4531-4536 (1996).		
	Sherrill, et al. "An Improved Synthesis and Resolution of 3-Amino-1,3 dihydro-5-phenyl-2H-1,4-benzodiazepine-2-ones." <i>J. Org. Chem.</i> 60:730-734 (1995).		
	Showell, et al. "High Affinity and Potent, Water-Soluble 5-Amino-1,4-Benzodiazepine CCKB/Gastrin Receptor Antagonists Containing a Cationic Solubilizing Group." <i>J. Med. Chem.</i> 37:719-721 (1994).		
	Smith, et al. "β-APP Processing as a Therapeutic Target for Alzheimer's Disease." <i>Current Pharmaceutical Design.</i> 3:439-445 (1997).		
	Stewart. "Syntheses of L-Kynurenine Peptides Conducted Without Masking the Side-Chain Amino Group." <i>Aust. J. Chem.</i> 33: 633-640 (1980).		
	Van Niel, et al. "CCKB Selective Receptor Ligands: Novel 1,3,5-Trisubstituted Benzazepin-2-ones." <i>Bioorganic &amp; Medicinal Chemistry Letters.</i> 5(13):1421-1426 (1995).		
	Varnavas, et al. "Synthesis of New Benzodiazepine Derivatives as Potential Cholecystokinin Antagonists." <i>Il Farmaco.</i> 46(2):391-401 (1991).		
	Waldmann, et al. "Selective Enzymatic Removal of Protecting Groups: The Phenylacetamide as Amino Protecting Group in Phosphopeptide Synthesis." <i>Tet. Lets.</i> 37(48): 8725-8728 (1996).		
	Warszawsky, et al. "The Synthesis of Aminobenzazepinones as Anti-Phenylalanine Dipeptide Mimics and Their Use in NEP Inhibition." <i>Bioorg. &amp; Med. Chem. Lets.</i> 6(8): 957-962 (1996).		
	Zoller, et al. "Aminoalkylation of Cercaptans with Glyoxylic Acid Derivatives." <i>Tetrahedron.</i> 31: 863-866 (1973).		
EXAMINER		DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.